RxDoctor Payments Data

Edward Crane, MD

Hematology & Oncology · Fairfield, OHNPI 1558301267

Payments from drug & device makers

$191,676in general payments, 2019–2025

Across 424 payments — averaging $452.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$55K
  • AstraZeneca$44K
  • E.r. Squibb & Sons, L.L.C.$37K
  • Genentech USA, Inc.$27K
  • Novartis$15K
  • Pfizer$10K
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$19,27911%
  • Speaking & faculty fees$146,63781%
  • Travel & lodging$6,3043%
  • Food & beverage$9,1815%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.44$54,961
AstraZeneca(2 entities)44$43,782
E.r. Squibb & Sons, L.L.C.40$36,898
Genentech USA, Inc.40$27,254
Novartis38$14,733
Pfizer22$10,299
Pharmacyclics LLC, An Abbvie Company13$382
AbbVie13$277
Eisai Inc.27$212
Merck9$193
Bristol Myers Squibb8$153
GSK7$148
Regeneron Healthcare Solutions, Inc.8$138
Incyte Corporation6$134
Sirtex Medical Inc1$131
Seagen Inc.7$125
Johnson & Johnson(2 entities)6$112
Lilly USA, LLC6$110
Gilead(2 entities)7$103
Amgen6$102
Astellas Pharma US Inc5$96
Sanofi4$94
Ipsen Biopharmaceuticals, Inc4$78
EMD Serono, Inc.2$64
Cumberland Pharmaceuticals, Inc.3$61
Novo Nordisk3$60
AVEO Pharmaceuticals, Inc.3$57
Stemline Therapeutics Inc.3$57
Johnson & Johnson Surgical Vision, Inc.1$54
Sumitomo Pharma America, Inc.3$52
Array Biopharma Inc3$48
Bayer3$47
Myovant Sciences Inc.2$39
Blueprint Medicines Corporation2$37
Geron Corporation1$34
Taiho Oncology, Inc.2$34
Puma Biotechnology, Inc.2$33
Secura Bio, Inc.2$31
Genmab U.S., Inc.1$26
Tersera Therapeutics LLC1$26
Tempus AI, Inc1$26
Immunocore Limited1$23
Takeda Pharmaceuticals U.S.A., Inc.1$22
Sun Pharmaceutical Industries Inc.1$21
Accord Healthcare, Inc.1$21
Karyopharm Therapeutics Inc.1$20
Springworks Therapeutics, Inc.1$20
Beigene USA, Inc.1$18
Rigel Pharmaceuticals, Inc.1$18
ADC Therapeutics America, Inc.1$18
Mirati Therapeutics, Inc.1$18
Deciphera Pharmaceuticals Inc.1$18
Pharmaessentia USA Corporation1$18
Servier Pharmaceuticals LLC1$17
Kyowa Kirin, Inc.1$17
Jazz Pharmaceuticals Inc.1$17
Spectrum Pharmaceuticals Inc.1$17
Adaptive Biotechnologies Corporation1$16
Recordati_rare_diseases_inc.1$15
Sobi, Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,676 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$155,112
Medicare patients
421
Services billed
1,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$623,733
OrserduElacestrant Hcl26$602,456
BrukinsaZanubrutinib46$512,714
ImbruvicaIbrutinib25$405,591
KisqaliRibociclib Succinate21$332,535
VenclextaVenetoclax40$296,917
TagrissoOsimertinib Mesylate15$260,882
CalquenceAcalabrutinib Maleate15$231,178
Lenalidomide17$213,288
IbrancePalbociclib14$207,528
EliquisApixaban98$116,809
OxycontinOxycodone Hcl60$96,370
Imatinib Mesylate44$65,768
OrgovyxRelugolix14$35,666
XareltoRivaroxaban24$18,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$153$623,73331 claims
Stemline Therapeutics Inc.Orserdu$57$602,45626 claims
Beigene USA, Inc.Brukinsa$18$512,71446 claims
AstraZenecaTagrisso, Calquence$43,782$492,06030 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$382$405,59125 claims
NovartisKisqali$14,733$332,53521 claims
PfizerIbrance, Eliquis$10,299$324,336112 claims
AbbVieVenclexta$277$296,91740 claims
Sumitomo Pharma America, Inc.Orgovyx$52$35,66614 claims
Johnson & JohnsonXarelto$112$18,71824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Fairfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →